Harmony Biosciences Holdings annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Harmony Biosciences Holdings R&D Spending Growth & History (HRMY)
Harmony Biosciences Holdings's r&d spending was $189.6M for fiscal 2025.
View full Harmony Biosciences Holdings company overviewHarmony Biosciences Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $189.6M | $43.8M | +30.01% |
| 2024 | 2024-12-31 | $145.8M | $69.8M | +91.72% |
| 2023 | 2023-12-31 | $76.1M | $5.2M | +7.30% |
| 2022 | 2022-12-31 | $70.9M | $40.5M | +133.43% |
| 2021 | 2021-12-31 | $30.4M | $10.9M | +56.14% |
| 2020 | 2020-12-31 | $19.4M | −$50.1M | −72.06% |
| 2019 | 2019-12-31 | $69.6M | — | — |
Harmony Biosciences Holdings quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $46.6M | −$3.6M | −7.10% |
| Q1 2026 | 2026-03-31 | $69.4M | $34.8M | +100.88% |
| Q4 2025 | 2025-12-31 | $49.9M | $15.3M | +44.04% |
| Q3 2025 | 2025-09-30 | $55.0M | $29.6M | +116.50% |
| Q2 2025 | 2025-06-30 | $50.2M | −$13.4M | −21.11% |
| Q1 2025 | 2025-03-31 | $34.5M | $12.4M | +55.66% |
| Q4 2024 | 2024-12-31 | $34.7M | $4.4M | +14.39% |
| Q3 2024 | 2024-09-30 | $25.4M | $7.9M | +45.08% |
| Q2 2024 | 2024-06-30 | $63.6M | $48.6M | +324.76% |
| Q1 2024 | 2024-03-31 | $22.2M | $8.9M | +66.97% |
| Q4 2023 | 2023-12-31 | $30.3M | $20.2M | +200.30% |
| Q3 2023 | 2023-09-30 | $17.5M | −$23.0M | −56.84% |
| Q2 2023 | 2023-06-30 | $15.0M | $2.3M | +18.16% |
| Q1 2023 | 2023-03-31 | $13.3M | $5.7M | +75.36% |
| Q4 2022 | 2022-12-31 | $10.1M | $2.6M | +35.44% |
| Q3 2022 | 2022-09-30 | $40.5M | $28.8M | +245.41% |
| Q2 2022 | 2022-06-30 | $12.7M | $6.2M | +94.95% |
| Q1 2022 | 2022-03-31 | $7.6M | $2.9M | +61.96% |
| Q4 2021 | 2021-12-31 | $7.5M | −$167,000 | −2.19% |
| Q3 2021 | 2021-09-30 | $11.7M | $7.5M | +177.52% |
| Q2 2021 | 2021-06-30 | $6.5M | $2.3M | +55.86% |
| Q1 2021 | 2021-03-31 | $4.7M | $1.2M | +36.37% |
| Q4 2020 | 2020-12-31 | $7.6M | — | — |
| Q3 2020 | 2020-09-30 | $4.2M | −$106,000 | −2.44% |
| Q2 2020 | 2020-06-30 | $4.2M | — | — |
| Q1 2020 | 2020-03-31 | $3.4M | — | — |
| Q3 2019 | 2019-09-30 | $4.3M | — | — |
Harmony Biosciences Holdings r&d spending trends
Over the last five fiscal years, Harmony Biosciences Holdings's r&d spending increased from $19.4M to $189.6M, a change of $170.1M. The latest reported quarter, Q2 2026, shows $46.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Harmony Biosciences Holdings source filings ↗